Serum Omentin-1 Level as a Biomarker in Prostate Cancer
Keywords:
Diagnostic biomarkers, Omentin-1, Prostate cancer.Abstract
Objective: To evaluate serum omentin-1 levels in prostate cancer patients relative to healthy controls and to assess its variation between tumor stages and Gleason score categories.
Methodology: This case-control research involved 176 participants (88 prostate cancer patients and 88 controls) from the National Teaching Oncology Hospital in Najaf, Iraq. Serum omentin-1 concentrations were verified by ELISA tests, and relationships with PSA, BMI were measured. ROC analysis was used to assess diagnostic efficacy.
Results: Omentin-1 levels were markedly elevated in prostate cancer patients (43.4 ± 22.6 ng/mL) compared to controls (26.1 ± 6.6 ng/mL, p < 0.01). ROC analysis showed reasonable diagnostic accuracy (AUC = 0.73).
Conclusion: Serum omentin-1 levels are elevated in prostate cancer, and no significant differences were observed across tumor stages or Gleason score categories, indicating that its elevation does not appear to be stage-dependent in this cohort. Further studies are needed to elucidate the mechanistic role of omentin-1 in prostate carcinogenesis, as well as its diagnostic and prognostic potential.
Downloads
Published
Issue
Section
License
West Asia Organization for Cabcer Prevention retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License 4 (This permits anyone to copy, distribute, transmit and adapt the published work, provided the original work and source are appropriately cited).





3.jpg)





